LFCR
LIFECORE BIOMEDICAL, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 15 ▲ Lifecore Biomedical announced a new commercial manufacturing agreeme…
- Jul 2 ▼ Lifecore Biomedical disclosed that holders of all 49,263 outstanding…
- Jul 28 Contract: Lifecore Biomedical Signs Three New Customer Agreements
- Sep 28 ▲ Lifecore Biomedical has entered into a definitive merger agreement t…
- Sep 28 Trading halt: Trading Halt: LFCR, T1 (News Pending)
- Sep 28 ▲ Legion Partners Asset Management filed an amended Schedule 13D discl…
- Sep 28 ▲ Lifecore Biomedical entered into a definitive merger agreement to be…
- Sep 28 ▲ Lifecore Biomedical announced it will be acquired by Webster Equity…
- Sep 29 ▼ Barrington Research downgrades
- Oct 15 ▲ Short interest falls 27.2% to 1.80M
- Nov 4 ▼ Lifecore Biomedical reported Q3 2026 revenue of $25.3M, down 18.6% Y…
- Nov 13 Lifecore Biomedical is being acquired by affiliates of Webster Equit…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 9 added (0 new), 11 trimmed or exited.
- AnalystsMIXED
0 of 10 rate it Buy or better. Price is above every target.
- EstimatesRISING
Current-quarter EPS estimate −$0.182 → −$0.100 over 90 days.
- Short sellersSTEADY
Short interest −4.5% to 1.72M shares. 3.5 days to cover, ≈4.5% of shares.
- TrendRANGE
10% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | ADD | $1.7M |
| Allspring Global Investments Holdings, LLC | ADD | $1.1M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.1M |
| LPL Financial LLC | TRIM | $954.1K |
| UBS Group AG | TRIM | $361.5K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $262.4K |
| Squarepoint Ops LLC | TRIM | $153.2K |
| SIMPLEX TRADING, LLC | TRIM | $112.7K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is above the highest target. Median implies −2%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 29, 2026 | Barrington Research DOWNGRADE | Market Perform |
| Sep 28, 2026 | William Blair DOWNGRADE | Market Perform |
| Jun 16, 2026 | Barrington Research MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
HOUDE LOVAS KATRINA Director Jun 4, 2026 | AWARD | 25,907 sh |
Korenberg Matthew E Director Jun 4, 2026 | AWARD | 25,907 sh |
Johnson Paul Harold Director Jun 4, 2026 | AWARD | 25,907 sh |
Aryeh Jason Director Jun 4, 2026 | AWARD | 25,907 sh |
Antunes Humberto Calheiros Director Jun 4, 2026 | AWARD | 25,907 sh |
Schechter Joshua Director Jun 4, 2026 | AWARD | 25,907 sh |
OBUS NELSON Director Jun 4, 2026 | AWARD | 25,907 sh |
Kiper Christopher S Director Jun 4, 2026 | AWARD | 25,907 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.10 | -$0.14–-$0.05 | +0.0% | $37.7M |
| Next Q | -$0.28 | -$0.30–-$0.27 | +0.0% | $27.1M |
| Current FY | -$1.83 | -$1.83–-$1.83 | -81.8% | $120.4M |
| Next FY | -$0.88 | -$1.08–-$0.76 | +0.0% | $131.0M |
Short side
FINRA· Oct 30, 2026| Sep 28, 2026 | Resumption Scheduled | Resumed |
SecBot reports
14 filings · 6 press releases · 3 bullish · 4 bearish · 7 neutral- NEUTRAL SC 13G/ANov 16, 2026
Greenhaven Road Investment Management filed an amended Schedule 13G, disclosing a 7.6% passive stake in Lifecore Biomedical as of September 30, 2026, unchanged from the prior filing. The filing confirms the investor remains a passive holder with no control intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL DEFM14ANov 13, 2026
Lifecore Biomedical is being acquired by affiliates of Webster Equity Partners for $6.28 per share…
The merger is fully financed with no financing condition, HSR clearance obtained, and ~27.4% of votes already committed. The key remaining condition is stockholder approval at the December 23…
- NEUTRAL 8-K, DEFA14ANov 5, 2026
Lifecore Biomedical disclosed that the DOJ and FTC granted early termination of the HSR Act…
Monitor the special meeting date and stockholder vote results for the merger; the CVR distribution terms and any potential superior proposals are key uncertainties.
- BEARISH 8-KNov 4, 2026
Lifecore Biomedical reported Q3 2026 revenue of $25.3M, down 18.6% YoY, and a GAAP net loss of…
Monitor the pending merger closing timeline and any updates on the CVR valuation. The revenue decline continues a trend from prior quarters, but the merger at a fixed price caps downside for…
All LFCR filing & press-release reports (20)
- SC 13G/A reportNov 16, 2026
- DEFM14A reportNov 13, 2026
- 8-K, DEFA14A reportNov 5, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- PREM14A reportOct 30, 2026
- 8-K reportOct 20, 2026
- SC 13D/A reportSep 28, 2026
- DEFA14A reportSep 28, 2026
- 8-K reportSep 28, 2026
- PRESS-RELEASE reportSep 28, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 2, 2026
- PRESS-RELEASE reportJun 15, 2026
- 8-K reportJun 5, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 16, 2026
- PRESS-RELEASE reportMar 4, 2026